



Stock Market Indexes	Last	Change	1 Month	YTD	1 Year
Indonesia - JCI	6,277.23	▼ -0.51%	▲ 0.11%	▲ 4.99%	▲ 33.82%
Indonesia - LQ45	939.63	▼ -0.37%	▼ -2.05%	▲ 0.51%	▲ 28.37%
Indonesia - JII	614.99	▼ -0.15%	▼ -4.89%	▼ -2.45%	▲ 27.31%
US - Dow Jones	33,015.37	▲ 0.58%	▲ 4.95%	▲ 7.87%	▲ 63.54%
Europe - Stoxx 600	424.91	▼ -0.45%	▲ 2.64%	▲ 6.49%	▲ 49.29%
Asia ex. Japan - MXFEJ	838.32	▼ -0.09%	▼ -6.80%	▲ 4.78%	▲ 60.24%
Hong Kong - Hang Seng	29,034.12	▲ 0.02%	▼ -5.57%	▲ 6.62%	▲ 25.89%
Malaysia - KLCI	1,624.97	▲ 0.06%	▲ 1.05%	▼ -0.14%	▲ 26.89%
Philippines - PCOMP	6,566.83	▲ 0.12%	▼ -5.64%	▼ -7.80%	▲ 23.08%
Singapore - STI	3,109.65	▲ 0.13%	▲ 6.08%	▲ 9.35%	▲ 24.60%
South Korea - KOSPI	3,047.50	▼ -0.64%	▼ -3.16%	▲ 6.06%	▲ 77.71%
Taiwan - TWSE	16,215.82	▼ -0.60%	▼ -0.90%	▲ 10.07%	▲ 66.87%
Thailand - SET	1,566.76	▲ 0.17%	▲ 2.89%	▲ 7.85%	▲ 49.77%
<b>Bond Index</b>					
IBPA Indonesia Government Bond Total Return Index	332.74	▲ 0.04%	▼ -2.53%	▼ -2.93%	▲ 10.80%
<b>Exchange Rate</b>					
USD-IDR	14,428.00	▼ -0.12%	▼ -3.72%	▼ -3.84%	▲ 3.38%

Source: Bloomberg. Data as of 17 Mar 2021.



## Ministry of Health: Almost 100% of Health Workers Have Been Vaccinated the First Dose of Covid-19 Vaccine

The target of Covid-19 vaccination for health workers (health workers) is 1,468,764. However, based on data from the Ministry of Health (Kemkes) as of Wednesday (17/2021), the number of health workers who had received the first dose of vaccination was 97.48% or 1,431,731. Meanwhile, 82.25% or 1,208,113 had received the second dose. The Head of the Center for Health Human Resources Education, Ministry of Health, Sugiyanto said, the Ministry of Health made every effort so that vaccinations to health workers were immediately completed. Sugiyanto said that the Covid-19 vaccine for these health workers was still incomplete, because there were several obstacles such as 15% of health workers who had comorbidities such as high blood pressure so that the implementation of the vaccine had to be postponed and rescheduled after the comorbids were resolved. In addition, vaccination for health workers in areas with limited access.

Investor Daily

## BPOM: The Astrazeneca Covid-19 Vaccine Will Not be used during the Examination Process

The Food and Drug Administration (BPOM) recommended that the Astrazeneca Covid-19 vaccine not be used in Indonesia during the study process, following the safety issue of the vaccine which was eventually suspended in 15 countries. "For caution, BPOM together with a team of experts from the National Commission on Drug Assessment, Komnas PP KIPi, and ITAGI conducted further studies since the safety issue was discovered. While it is still in the study process, the Astrazeneca Covid-19 vaccine is recommended not to be used," said the Head of BPOM. Penny Lukito in his statement in Jakarta, Wednesday (17/3/2021) night. BPOM said the delay was also carried out due to blood clotting cases including two fatal cases in Austria and Denmark that were suspected after injection of certain Astrazeneca Covid-19 vaccines (ABV5300, ABV3025 and ABV2856).

Bisnis Indonesia

## The Fed: US Inflation Will Soar This Year, But Interest Will Not Rise

The Federal Reserve (The Fed) said that the United States (US) economy is heading for the strongest growth in nearly 40 years. "Strong data is ahead of us," said Fed Chair Jerome Powell after a two-day policy meeting. Fed officials expect US economic growth to remain above trend for at least the next two years, at 3.3% in 2022 and 2.2% in 2023, compared to the 1.8% long-term growth potential forecast. Meanwhile, inflation is expected to surge to 2.4% this year, above the central bank's target of 2%. Although US inflation will surge, Powell said, the surge is only temporary that will not change the Fed's pledge to keep its benchmark interest rate near zero as part of efforts to ensure the economic wounds from the pandemic heal completely.

Kontan

Disclaimer : This document is made only as public information, and on specific investment target, individuals specific preference and allocation has not included in this document. You don't have to depend on this document as investment recommendation. If you have interest of anything about investment product, or if you do not have confidence on investment decision, you have to search financial recommendation from your professional advisor. Information that provided in this document are from trustable source, however, Allianz does not guarantee data accuracy. Opinion or prediction can changed without any prior information, and for that Allianz strictly refuse each and every responsibility on statement and guarantation, imply or not imply, stated in here or not stated.